Results 111 to 120 of about 19,663 (194)

Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer

, 2014
Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition ...
Tan, Weiwei, Zheng, Zongli, Iafrate, A. John, Stephenson, Patricia, Solomon, Benjamin J., Tye, Lesley M., Wilner, Keith D., Shreeve, S. Martin, Salgia, Ravi, Ou, Sai-Hong I., Doebele, Robert C., Riely, Gregory J., Camidge, D. Ross, Christensen, James G., Shapiro, Geoffrey I., Costa, Daniel B., Shaw, Alice T., Varella-Garcia, Marileila, Clark, Jeffrey W., Long Phi Le, Bang, Yung-Jue   +20 more
core   +1 more source

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

International Medical Case Reports Journal, 2020
Pietro Di Marino,1 Gianluca Mannetta,2 Consiglia Carella,3 Antonino Grassadonia,3 Nicola Tinari,3 Clara Natoli,3 Michele De Tursi3 1Clinical Oncology Unit, S.S.
Di Marino P, Mannetta G, Carella C, Grassadonia A, Tinari N, Natoli C, De Tursi M   +6 more
doaj  

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients [PDF]

, 2017
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were ...
Ceccon, Monica, King, Michael H., Chiriano, Gianpaolo, Cohen, Amos M., Redaelli, Sara, Deeren, Dries, Antolini, Laura, Sala, Elena, Stasia, Alessandra, Grube, Matthias, Gambacorti Passerini, Carlo, Mologni, Luca, Piazza, Rocco, Ordemann, Rainer, Farina, Francesca, Messa, Cristina, Steurer, Michael, Guerra, Luca, Bernard, Lea, Giudici, Giovanni, Mussolin, Lara   +20 more
core  

Use of crizotinib for refractory ALK-positive lymphomas

, 2017
Aim. To evaluate the safety and efficacy of crizotinib used in pediatric patients with relapsed or refractory ALK-positive anaplastic large-cell lymphoma (ALCL). Subjects and methods.
L N Shelikhova, M A Maschan, N V Myakova, D S Abramov, A A Maschan, V V Fominykh   +5 more
core   +1 more source

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

, 2014
Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.
Nishio, Makoto, Michellys, Pierre, Gainor, Justin, Lee, Christian, Fujita, Naoya, Sun, Frank, Mcnamara, Peter, Shaw, Alice, Awad, Mark, Katayama, Ryohei, Li, Nanxin, Mahmood, Sidra, Pferdekamper, Annemarie, Crystal, Adam, Harris, Jennifer, Engelman, Jeffery, Li, Jie, Kasibhatla, Shailaja, Kim, Sungjoon, Hua, Su, Yanagitani, Noriko, Lockerman, Elizabeth, Sun, Xiuying, Friboulet, Luc   +23 more
core   +1 more source

Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma. [PDF]

Int J Mol Sci
Li Y, Khan H, Demirsoy S, Younis M, Shi G, Valensi H, Bernhardt W, Lee J, Machtay M, Aregawi D, Glantz M, Giglio P, Yang S, Schell T, Walter V, Uzun Y, Olmez I.   +16 more
europepmc   +1 more source

Heterogeneity of thromboembolic risk across ALK inhibitors: a retrospective real-world study identifying crizotinib-specific signals and high-risk subpopulations. [PDF]

Front Pharmacol
Hu R, Ai Q, Zhang H, Liu M, Qiu Y, He Y.
europepmc   +1 more source

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study. [PDF]

MedComm (2020)
Zou Z, Zheng X, Tian P, Liu Z, Hu J, Fang Y, Xia Y, Ye F, Lv T, Li L, Zhong D, Zhou J, Chu Q, Shi M, Han C, Cao B, Huang D, Guo H, Lin G.   +18 more
europepmc   +1 more source

Long-Term Outcomes and Prognostic Factors in Metastatic <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center. [PDF]

Cancers (Basel)
Koçanoğlu A, Ünsal O, Kuş F, Gürçay N, Zeynelgil E, Düzköprü Y, Karakaya S.   +6 more
europepmc   +1 more source

Current Management and the New Paradigm for ALK+ NSCLC After CROWN. [PDF]

Cancers (Basel)
Shi S, Christopoulos P.
europepmc   +1 more source